Non-AIDS primary CNS lymphoma: First example of a durable response in a primary brain tumor using enhanced chemotherapy delivery without cognitive loss and without radiotherapy

Suellen A. Dahlborg, W. David Henner, John R. Crossen, Mara Tableman, Annie Petrillo, Rita Braziel, Edward Neuwelt

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

PURPOSE: Radiographic tumor response and survival were evaluated in patients receiving methotrexate-based chemotherapy with osmotic blood-brain barrier disruption with or without antecedent cranial radiation. ■ PATIENTS AND METHODS: Fifty-eight non-AIDS patients (38 males, 20 females) with histologically confirmed primary central nervous system lymphoma, primarily large cell or immunoblastic, were treated at the Oregon Health Sciences University from January 1982 through March 1992. Group 1 patients (n=19) received cranial radiation prior to referral; Group 2 (n=39) received initial blood-brain barrier disruption chemotherapy. Ages ranged from 5 to 71 years (median, 57); Karnofsky performance status was 40% to 100% on inclusion (median, 80) and all underwent extensive baseline neuropsychological evaluation. ■ RESULTS: There was no significant difference in patient characteristics between the two groups. In 15 evaluable Group 1 patients, 14 demonstrated objective response and 7 of 14 (50%) achieved complete response. In Group 2, 34 of 35 evaluable patients demonstrated objective response, including 29 of 34 with complete response. Estimated median survival times for Group 1 and Group 2 patients were 16 and 41 months, respectively. Currently, 19 Group 2 patients and 2 Group 1 patients are alive. Extensive neuropsychological follow-up (up to 7 years from baseline) was completed in 23 patients, which demonstrated preservation or improved cognitive function in those receiving initial chemotherapy and blood-brain barrier disruption, most notably in patients older than 60 years. ■ CONCLUSIONS: A plateau in survival curves suggests that a portion of primary central nervous system lymphoma patients may be cured with chemotherapy and blood-brain barrier disruption without the neurologic sequelae associated with cranial radiation.

Original languageEnglish (US)
Pages (from-to)166-174
Number of pages9
JournalCancer Journal from Scientific American
Volume2
Issue number3
StatePublished - 1996

Fingerprint

Brain Neoplasms
Lymphoma
Radiotherapy
Drug Therapy
Blood-Brain Barrier
Radiation
Survival
Central Nervous System
Karnofsky Performance Status
Methotrexate
Cognition
Nervous System
Referral and Consultation

Keywords

  • Central nervous system
  • Cytoxan
  • Lymphoma
  • Methotrexate

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Non-AIDS primary CNS lymphoma : First example of a durable response in a primary brain tumor using enhanced chemotherapy delivery without cognitive loss and without radiotherapy. / Dahlborg, Suellen A.; Henner, W. David; Crossen, John R.; Tableman, Mara; Petrillo, Annie; Braziel, Rita; Neuwelt, Edward.

In: Cancer Journal from Scientific American, Vol. 2, No. 3, 1996, p. 166-174.

Research output: Contribution to journalArticle

@article{8fdb5ea3cdac4514a7ba544f876fad46,
title = "Non-AIDS primary CNS lymphoma: First example of a durable response in a primary brain tumor using enhanced chemotherapy delivery without cognitive loss and without radiotherapy",
abstract = "PURPOSE: Radiographic tumor response and survival were evaluated in patients receiving methotrexate-based chemotherapy with osmotic blood-brain barrier disruption with or without antecedent cranial radiation. ■ PATIENTS AND METHODS: Fifty-eight non-AIDS patients (38 males, 20 females) with histologically confirmed primary central nervous system lymphoma, primarily large cell or immunoblastic, were treated at the Oregon Health Sciences University from January 1982 through March 1992. Group 1 patients (n=19) received cranial radiation prior to referral; Group 2 (n=39) received initial blood-brain barrier disruption chemotherapy. Ages ranged from 5 to 71 years (median, 57); Karnofsky performance status was 40{\%} to 100{\%} on inclusion (median, 80) and all underwent extensive baseline neuropsychological evaluation. ■ RESULTS: There was no significant difference in patient characteristics between the two groups. In 15 evaluable Group 1 patients, 14 demonstrated objective response and 7 of 14 (50{\%}) achieved complete response. In Group 2, 34 of 35 evaluable patients demonstrated objective response, including 29 of 34 with complete response. Estimated median survival times for Group 1 and Group 2 patients were 16 and 41 months, respectively. Currently, 19 Group 2 patients and 2 Group 1 patients are alive. Extensive neuropsychological follow-up (up to 7 years from baseline) was completed in 23 patients, which demonstrated preservation or improved cognitive function in those receiving initial chemotherapy and blood-brain barrier disruption, most notably in patients older than 60 years. ■ CONCLUSIONS: A plateau in survival curves suggests that a portion of primary central nervous system lymphoma patients may be cured with chemotherapy and blood-brain barrier disruption without the neurologic sequelae associated with cranial radiation.",
keywords = "Central nervous system, Cytoxan, Lymphoma, Methotrexate",
author = "Dahlborg, {Suellen A.} and Henner, {W. David} and Crossen, {John R.} and Mara Tableman and Annie Petrillo and Rita Braziel and Edward Neuwelt",
year = "1996",
language = "English (US)",
volume = "2",
pages = "166--174",
journal = "Cancer journal (Sudbury, Mass.)",
issn = "1528-9117",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "3",

}

TY - JOUR

T1 - Non-AIDS primary CNS lymphoma

T2 - First example of a durable response in a primary brain tumor using enhanced chemotherapy delivery without cognitive loss and without radiotherapy

AU - Dahlborg, Suellen A.

AU - Henner, W. David

AU - Crossen, John R.

AU - Tableman, Mara

AU - Petrillo, Annie

AU - Braziel, Rita

AU - Neuwelt, Edward

PY - 1996

Y1 - 1996

N2 - PURPOSE: Radiographic tumor response and survival were evaluated in patients receiving methotrexate-based chemotherapy with osmotic blood-brain barrier disruption with or without antecedent cranial radiation. ■ PATIENTS AND METHODS: Fifty-eight non-AIDS patients (38 males, 20 females) with histologically confirmed primary central nervous system lymphoma, primarily large cell or immunoblastic, were treated at the Oregon Health Sciences University from January 1982 through March 1992. Group 1 patients (n=19) received cranial radiation prior to referral; Group 2 (n=39) received initial blood-brain barrier disruption chemotherapy. Ages ranged from 5 to 71 years (median, 57); Karnofsky performance status was 40% to 100% on inclusion (median, 80) and all underwent extensive baseline neuropsychological evaluation. ■ RESULTS: There was no significant difference in patient characteristics between the two groups. In 15 evaluable Group 1 patients, 14 demonstrated objective response and 7 of 14 (50%) achieved complete response. In Group 2, 34 of 35 evaluable patients demonstrated objective response, including 29 of 34 with complete response. Estimated median survival times for Group 1 and Group 2 patients were 16 and 41 months, respectively. Currently, 19 Group 2 patients and 2 Group 1 patients are alive. Extensive neuropsychological follow-up (up to 7 years from baseline) was completed in 23 patients, which demonstrated preservation or improved cognitive function in those receiving initial chemotherapy and blood-brain barrier disruption, most notably in patients older than 60 years. ■ CONCLUSIONS: A plateau in survival curves suggests that a portion of primary central nervous system lymphoma patients may be cured with chemotherapy and blood-brain barrier disruption without the neurologic sequelae associated with cranial radiation.

AB - PURPOSE: Radiographic tumor response and survival were evaluated in patients receiving methotrexate-based chemotherapy with osmotic blood-brain barrier disruption with or without antecedent cranial radiation. ■ PATIENTS AND METHODS: Fifty-eight non-AIDS patients (38 males, 20 females) with histologically confirmed primary central nervous system lymphoma, primarily large cell or immunoblastic, were treated at the Oregon Health Sciences University from January 1982 through March 1992. Group 1 patients (n=19) received cranial radiation prior to referral; Group 2 (n=39) received initial blood-brain barrier disruption chemotherapy. Ages ranged from 5 to 71 years (median, 57); Karnofsky performance status was 40% to 100% on inclusion (median, 80) and all underwent extensive baseline neuropsychological evaluation. ■ RESULTS: There was no significant difference in patient characteristics between the two groups. In 15 evaluable Group 1 patients, 14 demonstrated objective response and 7 of 14 (50%) achieved complete response. In Group 2, 34 of 35 evaluable patients demonstrated objective response, including 29 of 34 with complete response. Estimated median survival times for Group 1 and Group 2 patients were 16 and 41 months, respectively. Currently, 19 Group 2 patients and 2 Group 1 patients are alive. Extensive neuropsychological follow-up (up to 7 years from baseline) was completed in 23 patients, which demonstrated preservation or improved cognitive function in those receiving initial chemotherapy and blood-brain barrier disruption, most notably in patients older than 60 years. ■ CONCLUSIONS: A plateau in survival curves suggests that a portion of primary central nervous system lymphoma patients may be cured with chemotherapy and blood-brain barrier disruption without the neurologic sequelae associated with cranial radiation.

KW - Central nervous system

KW - Cytoxan

KW - Lymphoma

KW - Methotrexate

UR - http://www.scopus.com/inward/record.url?scp=0001613639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0001613639&partnerID=8YFLogxK

M3 - Article

C2 - 9166517

AN - SCOPUS:0001613639

VL - 2

SP - 166

EP - 174

JO - Cancer journal (Sudbury, Mass.)

JF - Cancer journal (Sudbury, Mass.)

SN - 1528-9117

IS - 3

ER -